SL Therapeutics, Inc. (XKON: 258540)

Market Cap	4.68B
Revenue	n/a
Net Income	n/a
Shares Out	5.21M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,008
Average Volume	1,720
Open	730.00
Previous Close	818.00
Day's Range	696.00 - 897.00
52-Week Range	536.00 - 2,260.00
Beta	-0.19
RSI	55.02
Earnings Date	n/a

About SL Therapeutics

SL Therapeutics, Inc. engages in cell therapy and medical device businesses. The company develops cell therapeutic solutions based on its cell reprogramming technology to treat various diseases with a focus on spinal cord injury, and age and genetically related diseases; and hair follicle cells, skin cells, and cells of the central nervous system. It also manufactures automated magnetic resonance imaging systems; and Supra Elite and Dexino bone mineral density measurement devices. The company was formerly known as StemLab Inc. SL Therapeutics, ...

• Industry: Commercial Physical and Biological Research
• Founded: 2011
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 258540